US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
WO2002051438A2
(fr)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Utilisation de rgm et de ses modulateurs
|
EP1519740A4
(fr)
*
|
2001-08-17 |
2005-11-09 |
Lilly Co Eli |
Amelioration rapide des processus cognitifs dans les etats pathologiques lies a l'a-beta
|
PT1944040E
(pt)
*
|
2001-08-17 |
2012-10-31 |
Univ Washington |
Método de avaliação para a doença de alzheimer
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7575747B2
(en)
|
2003-02-10 |
2009-08-18 |
Applied Molecular Evolution |
Aβ binding molecules
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
US20110142858A1
(en)
*
|
2004-06-07 |
2011-06-16 |
Ramot At Tel Aviv University Ltd. |
Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
|
CA2589017A1
(fr)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Anticorps amyloide beta utilises afin d'ameliorer la cognition
|
JP2008523815A
(ja)
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EA201100177A1
(ru)
|
2005-06-17 |
2011-06-30 |
Элан Фарма Интернэшнл Лимитед |
СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
|
CN103172738A
(zh)
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
WO2007024715A2
(fr)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Immunoglobuline a deux domaines variables et utilisations de celle-ci
|
EP2500354A3
(fr)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunoglobuline à double domaine variable et ses utilisations
|
GB0519398D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Antisoma Plc |
Biological materials and uses thereof
|
CA2624562A1
(fr)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
|
CA2631195C
(fr)
|
2005-11-30 |
2016-04-05 |
Abbott Laboratories |
Anticorps monoclonaux et utilisation de ceux-ci
|
CN101432302A
(zh)
|
2005-11-30 |
2009-05-13 |
艾博特公司 |
抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法
|
AU2013200177B2
(en)
*
|
2005-11-30 |
2014-10-02 |
Abbvie Deutschland Gmbh & Co Kg |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
PT1960428E
(pt)
|
2005-12-12 |
2011-10-07 |
Hoffmann La Roche |
Anticorpos glicosilados na região variável contra beta-amilóide 4
|
PT2361638E
(pt)
|
2005-12-12 |
2014-04-17 |
Ac Immune Sa |
Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
EP2046833B9
(fr)
|
2006-07-14 |
2014-02-19 |
AC Immune S.A. |
Anticorps humanisé contre l'amyloid beta
|
KR101544108B1
(ko)
|
2006-09-08 |
2015-08-13 |
애브비 바하마스 리미티드 |
인터루킨-13 결합 단백질
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
CN101981053B
(zh)
|
2007-01-18 |
2013-11-13 |
伊莱利利公司 |
聚乙二醇化的AβFAB
|
EP2121633A2
(fr)
|
2007-02-12 |
2009-11-25 |
Merck & Co., Inc. |
Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
|
EP2124952A2
(fr)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Méthode de traitement d'amyloïdoses
|
NZ579310A
(en)
|
2007-03-01 |
2012-03-30 |
Probiodrug Ag |
Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
|
DK2142514T3
(da)
|
2007-04-18 |
2015-03-23 |
Probiodrug Ag |
Thioureaderivater som glutaminylcyclase-inhibitorer
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US7931899B2
(en)
|
2007-05-14 |
2011-04-26 |
Medtronic, Inc |
Humanized anti-amyloid beta antibodies
|
US8323654B2
(en)
|
2007-05-14 |
2012-12-04 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
PE20090766A1
(es)
*
|
2007-06-12 |
2009-07-09 |
Ac Immune Sa |
Anticuerpo igg1 humanizado
|
EP2182983B1
(fr)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
|
CA2701793C
(fr)
|
2007-10-05 |
2017-04-25 |
Genentech, Inc. |
Utilisation d'anticorps beta anti-amyloides contre les maladies occulaires
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2586797A3
(fr)
*
|
2007-11-27 |
2013-07-24 |
Medtronic, Inc. |
Anticorps anti-amyloïdes bêta humanisés
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2009136382A2
(fr)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Anticorps contre le récepteur des produits terminaux de glycation avancée (rage) et leurs utilisations
|
UY31861A
(es)
|
2008-06-03 |
2010-01-05 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
MX2010013239A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
NZ611324A
(en)
|
2009-03-05 |
2015-02-27 |
Abbvie Inc |
Il-17 binding proteins
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
UY32870A
(es)
|
2009-09-01 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8486940B2
(en)
|
2009-09-11 |
2013-07-16 |
Probiodrug Ag |
Inhibitors
|
RU2012119756A
(ru)
|
2009-10-15 |
2013-11-20 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011070045A1
(fr)
|
2009-12-08 |
2011-06-16 |
Abbott Gmbh & Co. Kg |
Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes
|
EP2542549B1
(fr)
|
2010-03-03 |
2016-05-11 |
Probiodrug AG |
Inhibiteurs de glutaminyl cyclase
|
BR112012022478B1
(pt)
|
2010-03-10 |
2021-09-21 |
Probiodrug Ag |
Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
UY33386A
(es)
|
2010-05-14 |
2011-12-30 |
Abbott Laboratoires |
Proteínas de unión a il-1
|
WO2012006500A2
(fr)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
SG187173A1
(en)
|
2010-07-30 |
2013-02-28 |
Ac Immune Sa |
Safe and functional humanized anti beta-amyloid antibody
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
DK2603528T3
(en)
|
2010-08-10 |
2016-11-28 |
Glycotope Gmbh |
FAB-glycosylated ANTIBODIES
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
JP6009455B2
(ja)
|
2010-12-21 |
2016-10-19 |
アッヴィ・インコーポレイテッド |
Il−1アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
EP4086338A1
(fr)
*
|
2011-03-17 |
2022-11-09 |
Minerva Biotechnologies Corporation |
Procédé d'obtention de cellules souches pluripotentes
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
WO2012172449A1
(fr)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactames convenant comme inhibiteurs des bêta-sécrétases
|
JP2014520847A
(ja)
|
2011-07-13 |
2014-08-25 |
アッヴィ・インコーポレイテッド |
抗il−13抗体を使用して喘息を治療するための方法および組成物
|
JP6043355B2
(ja)
|
2011-08-31 |
2016-12-14 |
ファイザー・インク |
ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
EP2771360A1
(fr)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Agents de liaison immunologique dirigés contre la sclérostine
|
MX2014008101A
(es)
|
2011-12-30 |
2014-09-25 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
|
NZ714482A
(en)
|
2012-01-27 |
2017-08-25 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
WO2013164730A1
(fr)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
|
JP6189948B2
(ja)
|
2012-06-29 |
2017-08-30 |
ファイザー・インク |
LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
JP2012233002A
(ja)
*
|
2012-08-03 |
2012-11-29 |
Janssen Alzheimer Immunotherapy |
認知の改善における使用のためのアミロイドβ抗体
|
WO2014045162A1
(fr)
|
2012-09-20 |
2014-03-27 |
Pfizer Inc. |
Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
TW201811825A
(zh)
|
2012-11-01 |
2018-04-01 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
EP2931731A1
(fr)
|
2012-12-11 |
2015-10-21 |
Pfizer Inc. |
Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
|
CA2893333C
(fr)
|
2012-12-19 |
2017-10-24 |
Pfizer Inc. |
Composes hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues carbocycliques et heterocycliques
|
WO2014100542A1
(fr)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
Humanisation d'anticorps à haut rendement
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
US9915665B2
(en)
|
2012-12-28 |
2018-03-13 |
Abbvie Inc. |
High-throughput system and method for identifying antibodies having specific antigen binding activities
|
EP2948177A1
(fr)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Procédés destinés à optimiser la stabilité de domaines de protéines de liaison
|
JP2016507551A
(ja)
|
2013-02-13 |
2016-03-10 |
ファイザー・インク |
ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
BR112015019276A2
(pt)
|
2013-02-19 |
2017-07-18 |
Pfizer |
compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
CA2906407A1
(fr)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Antigenes recombinants ns3 de vhc et leurs mutants pour la detection d'anticorps amelioree
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
TW201512219A
(zh)
|
2013-03-15 |
2015-04-01 |
Abbvie Inc |
針對IL-1β及/或IL-17之雙特異性結合蛋白
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
ES2742078T3
(es)
|
2013-10-04 |
2020-02-13 |
Pfizer |
Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
AU2015231001A1
(en)
|
2014-03-21 |
2016-09-29 |
Abbvie Inc. |
Anti-EGFR antibodies and antibody drug conjugates
|
MX369074B
(es)
|
2014-04-01 |
2019-10-28 |
Pfizer |
Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa.
|
MD20160105A2
(ro)
|
2014-04-10 |
2017-03-31 |
Pfizer Inc. |
2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
|
WO2015165961A1
(fr)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Traitement et prévention de la maladie d'alzheimer
|
JP6713982B2
(ja)
|
2014-07-24 |
2020-06-24 |
ファイザー・インク |
ピラゾロピリミジン化合物
|
ES2733502T3
(es)
|
2014-08-06 |
2019-11-29 |
Pfizer |
Compuestos de imidazopiridazina
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
|
WO2016081643A1
(fr)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anticorps anti-récepteur de la transferrine et procédés d'utilisation
|
MX2017007491A
(es)
|
2014-12-10 |
2018-05-04 |
Genentech Inc |
Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
|
WO2016094881A2
(fr)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Protéines de liaison à lrp-8
|
PE20171318A1
(es)
|
2015-02-03 |
2017-09-07 |
Pfizer |
Ciclopropabenzofuranil-piridopirazindionas novedosas
|
WO2016160976A2
(fr)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Protéines de liaison au tnf monovalentes
|
SI3303395T1
(sl)
|
2015-05-29 |
2020-03-31 |
Abbvie Inc. |
Protitelesa proti CD40 in njihove uporabe
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3766885B1
(fr)
|
2015-06-17 |
2022-05-25 |
Pfizer Inc. |
Composés tricycliques comme inhibiteurs de la phosphodiesterase
|
CA2985718A1
(fr)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Anticorps anti-recepteur de la transferrine avec une affinite adaptee
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
AU2016325665A1
(en)
|
2015-09-24 |
2018-03-08 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用
|
JP2018534251A
(ja)
|
2015-09-24 |
2018-11-22 |
ファイザー・インク |
Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
PE20231655A1
(es)
|
2015-10-02 |
2023-10-17 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
NZ743881A
(en)
|
2016-02-06 |
2023-11-24 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
CN108699080B
(zh)
|
2016-02-23 |
2021-05-14 |
辉瑞公司 |
6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
|
CN116173232A
(zh)
|
2016-06-08 |
2023-05-30 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
US20190153108A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
CN109562168A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CN109600993A
(zh)
|
2016-06-08 |
2019-04-09 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
CA3027044A1
(fr)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anticorps anti-b7-h3 et conjugues anticorps-medicaments
|
BR112018075630A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de fármaco de anticorpo
|
BR112018075649A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
|
JP6751165B2
(ja)
|
2016-06-08 |
2020-09-02 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
CA3027178A1
(fr)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Conjugue anticorps-medicament anti-egfr
|
DK3478679T3
(da)
|
2016-07-01 |
2021-06-21 |
Pfizer |
5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
|
US20190177439A1
(en)
|
2016-08-16 |
2019-06-13 |
Epimab Biotherapeutics, Inc. |
Monovalent Asymmetric Tandem Fab Bispecific Antibodies
|
EP3544628A4
(fr)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
Protéines de liaison à 4-1bb et leurs utilisations
|
AU2018230236B2
(en)
|
2017-03-10 |
2022-05-19 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors
|
CA3056027A1
(fr)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Derives d'imidazo [4,5-c] quinoleine substitues cycliques
|
EP3612567B1
(fr)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anticorps anti-vtcn1 et conjugués anticorps-médicament
|
WO2018226992A1
(fr)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Inhibiteur d'agrégation de tau
|
FI3642202T3
(fi)
|
2017-06-22 |
2023-03-01 |
|
Dihydro-pyrrolo-pyridiinijohdannaisia
|
EP3574020B1
(fr)
|
2017-07-18 |
2024-05-15 |
The University of British Columbia |
Anticorps anti-bêta-amyloïde
|
US11453701B2
(en)
|
2017-08-18 |
2022-09-27 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
DK3768669T3
(da)
|
2018-03-23 |
2023-04-24 |
Pfizer |
Piperazinazaspiroderivater
|
AU2019263850A1
(en)
|
2018-05-03 |
2020-11-19 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
|
SI3794042T1
(sl)
|
2018-05-18 |
2024-07-31 |
Daiichi Sankyo Co., Ltd. |
Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
|
MX2021000235A
(es)
|
2018-07-17 |
2021-03-25 |
Jiangsu Hengrui Medicine Co |
Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.
|
KR20210100086A
(ko)
|
2018-10-04 |
2021-08-13 |
유니버시티 오브 로체스터 |
혈장 오스몰농도 조작에 의한 글림프 전달의 개선
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN115894689A
(zh)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
WO2023094525A1
(fr)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Conjugués anticorps-charge utile améliorés (apc) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
|
EP4186529A1
(fr)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Conjugués anticorps-charge utile améliorés (apcs) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
|
CN116333135A
(zh)
|
2021-12-24 |
2023-06-27 |
百奥泰生物制药股份有限公司 |
抗FRα抗体及其抗体药物偶联物和用途
|
WO2024127366A1
(fr)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Anticorps dirigés contre la protéine 1 contenant le domaine cub (cdcp1) et leurs utilisations
|